China's Biotech Industry

j17wang

j17wang

Senior Member
Registered Member
GulfLander said:
curious, how long in duration are these outlicensing deals? are they perpetual?
Click to expand...
They are commercially useful for the duration of the patent (20 year starting point). Keep in mind that a few years are eaten up during your clinical trials, but you also can get patent extension terms. Overall, you get about ~15 years of good earnings from them. But with new innovations, the timeline will likely reduce in the future as successor treatments are created, so there may be less value even before patent expiry.
 
PopularScience

PopularScience

Senior Member
Registered Member
First case in China! Blind person regains sight using invasive brain-computer interface; peak visual acuity reaches 0.1.

After a period of standardized rehabilitation training, the subjects can now recognize characters on the E-chart and walk independently indoors and through doors without assistance. The latest test data shows that the subjects' measured visual acuity has stabilized at 0.03, with a peak value of 0.1.

Please, Log in or Register to view URLs content!
 
Last edited:
PopularScience

PopularScience

Senior Member
Registered Member
Go watch the amazing embedded video.

On June 10, Professor Wei Wensheng's team at Peking University announced that their RNA editing technology, LEAPER, has achieved internationally leading results in the treatment of Duchenne muscular dystrophy (DMD), a serious and rare genetic disease.

Please, Log in or Register to view URLs content!
 
G

GulfLander

Brigadier
Registered Member
The US risks ceding healthcare and science preeminence to China if it doesn’t speed its systems for medical research and regulation, said Max Hodak, former president of Elon Musk’s Neuralink who now heads neurotechnology firm Science Corp.

“There is a very real possibility that without significant regulatory reform, if you’re a wealthy American, in 10 years, the only place you’ll be able to get your state-of-the-art cancer care is in Shanghai,” he said Wednesday at the Semafor Tech summit in San Francisco. “This is a thing we should be very mindful of. [China is] executing very competently.”
Click to expand...
Please, Log in or Register to view URLs content!
 
sunnymaxi

sunnymaxi

Colonel
Registered Member

Japanese pharma companies turn to China for drug discovery, growth​


Astellas Pharma will open a research and development center -- the company's first in China -- in Beijing as soon as this year.
The company already has sales and clinical trial facilities in Beijing and Shanghai, as well as a production base in Shenyang. The Beijing R&D hub will handle drug discovery.

Daiichi Sankyo is investing about 1.1 billion yuan ($162 million) to increase China production capacity by starting operations at a Shanghai pharmaceutical production facility in fiscal 2030. The plant is expected to make the company's flagship cancer treatment Enhertu, as well as Datroway, a new cancer drug that Daiichi Sankyo hopes to grow into a major earner.

Takeda Pharmaceutical and Eisai have partnered with Chinese biotech companies to expand their pools of drug candidates.
China's level of drug development is rapidly approaching that of the U.S., said Takeda President and CEO Christophe Weber, who pointed to advantages like lower costs and faster clinical trials.

Please, Log in or Register to view URLs content!
 
You must log in or register to reply here.
Top